Atezolizumab

Description

This page contains brief details about the drug atezolizumab, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Atezolizumab is an anticancer drug belonging to the group of medicines called Programmed death ligand – 1 inhibitor (PDL-1). It was officially approved for its medical use in the year 2016.

Mechanism of Action of Atezolizumab

Atezolizumab is a humanized monoclonal antibody that belongs to the category of programmed death ligand – 1. Programmed death ligand is a protein that facilitates the suppression of T-cells by binding with immune and tumor cells. This leads to a poor immune response against cancer cells. Atezolizumab Injection acts against the signals of programmed death ligand – 1 and improves immune response by exhibiting specific cytotoxic activity.

Uses of Atezolizumab

Atezolizumab is indicated for various types of cancer as a monotherapy and also along with other anticancer medications. It is usually prescribed to treat urothelial carcinoma, liver cancer (hepatocellular carcinoma), small cell and non-small cell lung cancer, triple-negative breast cancer, and melanoma.

Atezolizumab Dosage available

Atezolizumab Injection is intended for intravenous administration. Your physician will inject this medicine as an infusion for the first 60 minutes and if it is well tolerated, the subsequent infusions will be administered for 30 minutes.

Atezolizumab Injection is available as a single-use vial in doses 840mg/14ml and 1200mg/20ml. The ideal dosing for urothelial carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, and melanoma is 840mg every two weeks, 1200mg every 3 weeks, or 1680mg every four weeks.